Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Alliance Pharma deal an important step towards internationalisation, says City research house

The latest addition to the Alliance Pharma medicine chest represents an “important step to the internationalisation of the group”, according to a City research house. 
Alliance Pharma deal an important step towards internationalisation, says City research house

The latest addition to the Alliance Pharma (LON:APH) medicine chest represents an “important step to the internationalisation of the group”, according to the City research house Hardman & Co.

Alliance said last week it will pay US$11.5mln to acquire full ownership of obstetric drug Syntometrine from Swiss giant Novartis.

The speciality pharma group already owns the UK rights to the treatment, which is used in the final stages of labour.

However, Syntometrine sells in around a dozen other major territories, including Australia, South Africa, Malaysia and New Zealand.

Hardman is predicting Alliance’s overseas revenues will rise to around 30% of total sales in 2014, compared with just 18% last year.

Analysts point out the deal uses the blue-print that underpins company’s success – acquiring prescription drugs that require little or no marketing, but generate a solid revenue stream.

Outside the UK Syntometrine generates sales of US$3.2mln. 

Adjusting for inventories, Alliance has paid 3.5 times turnover and 5.5 times earnings for the product, specialist small-cap broker FinnCap said.   

“We believe is a fair price and in line with the multiples we have seen historically for such acquisitions.” 

At 11.30am, the shares were little changed at 37.9 pence, valuing Alliance Pharma at £94mln. In the past year the stock has increased in value by a third.

Ian Lyall
June 10 2013 Ian Lyall
Why Invest In Alliance Pharma? Read More Here

Register here to be notified of future APH Company articles

Timeline

Newswire
February 17

Related Articles

Wed
Clinigen is a drugs and pharma services specialist....
June 19
Collagen Solutions has set itself the goal of becoming a £100mln company in the next five years.
March 31 2014

Treatment was well-tolerated and showed signs of halting tumour progression at higher doses.

© Proactive Investors 2015